Sub-groups of the patient population may carry mutations in specific gene(s) that affect the response of that individual to a therapeutic. By individually knocking out each of ~19,000 genes, you can identify the genes that alter resistance or sensitivity to your compound.
Horizon has optimized 35+ cell lines for the standard CRISPR KO screen offering called ResponderSCREEN.
Choose 1, 2 or 4 cell lines from our pre-optimized panel, provide us with your compound and you will receive a list of genes that are important for your drug activity.
Horizon has licensed the use and commercialisation of CRISPR-Cas9 technology from The Broad Institute, ERS Genomics, Harvard University and Caribou BioSciences.
|Cell Line||Lineage||Cell Line||Lineage||Cell Line||Lineage|
|Whole genome CRISPR KO resistance screen in A375 melanoma cells|
Purpose: A proof of concept study to identify resistance factors against a BRAF kinase inhibitor Vemurafenib (PLX-4032) in A375 melanoma cells that carry a BRAF V600E gain-of-function mutation.
Figure 1. Ranking of the hits of the screen by